Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061141 | 0.93 | CA2 (0.44) | TSHRFAAHCA2CA1GRIK1 | |
| SCHEMBL10770826 | 0.86 | HDAC1 (0.39) | TSHRFAAHCA2CA1GRIK1 | |
| SCHEMBL9673462 | 0.85 | CPB2 (0.47) | TSHRFAAHCA2ZDHHC7CA1 | |
| SCHEMBL27451629 | 0.85 | CA2 (0.56) | TSHRFAAHCA2ZDHHC7CA1 | |
| SCHEMBL5599531 | 0.85 | CA2 (0.56) | TSHRFAAHCA2ZDHHC7CA1 | |
| SCHEMBL671483 | 0.85 | TSHR (0.47) | TSHRFAAHCA2ZDHHC7CA1 | |
| SCHEMBL5599769 | 0.85 | CPB2 (0.47) | TSHRFAAHCA2ZDHHC7CA1 | |
| SCHEMBL7165372 | 0.85 | CA2 (0.56) | TSHRFAAHCA2ZDHHC7CA1 | |
| SCHEMBL27451160 | 0.84 | TSHR (0.58) | TSHRFAAHCA2ZDHHC7CA1 | |
| SCHEMBL28238121 | 0.84 | TSHR (0.58) | TSHRFAAHCA2ZDHHC7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955171-A1 | MANUFACTURE PROCESS OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID | Novartis AG (CH) | 2015-12-16 | — | — | EP | claimed |
| EP-2955171-A1 | MANUFACTURE PROCESS OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID | Novartis AG (CH) | 2015-12-16 | — | — | EP | disclosed |
| EP-1838664-B1 | MANUFACTURE PROCESS OF N-SUBSTITUTED SALICYLAMIDES | NOVARTIS AG (CH) | 2015-07-15 | — | — | EP | disclosed |
| US-8461385-B2 | Manufacture process of organic compounds | NOVARTIS AG (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20090253811-A1 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-1838664-A1 | MANUFACTURE PROCESS OF N-SUBSTITUTED SALICYLAMIDES | Novartis AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006063821-A1 | MANUFACTURE PROCESS OF N-SUBSTITUTED SALICYLAMIDES | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253811-A1 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS | NT5C, AADAC, DDC | TSHR 4836/4885FAAH 2552/4885CA2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.